Clinical Trials Logo

Grey Zone Lymphoma clinical trials

View clinical trials related to Grey Zone Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02623920 Withdrawn - Follicular Lymphoma Clinical Trials

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

S-BR
Start date: December 16, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, use antibody to target chemotherapy in cancer cells. Drugs used in chemotherapy, such as bendamustine, work in different ways to kill cancer cells. Monoclonal antibodies, such as rituximab, kill the cancer cells directly, but also harness the immune system to kill the cancer cells. Adding brentuximab to rituximab may improve response rates in CD30 positive, CD20 positive Relapsed Refactory NHL.